Skip to main content
Fig. 1 (abstract P385). | Journal for ImmunoTherapy of Cancer

Fig. 1 (abstract P385).

From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part Two

Fig. 1 (abstract P385).

Escape from anti-PD-1 Ab Immunotherapy in a Transgenic Melanoma Model Involves the Recruitment of Gr-MDSCs. A. RNAseq differential gene expression analysis showing an upregulation of several CXCR2 ligands following anti-PD-1 ab escape in a transgenic BRAF(V600)-PTEN-/- melanoma model. B. RNAseq differential gene expression analysis demonstrating increased MDSC markers in BRAF(V600E)-PTEN-/- melanomas following escape from anti-PD-1 ab therapy. C. Immunohistochemistry and flow cytometry analysis demonstrating increased levels of Gr-MDSCs in anti-PD-1 ab-treated versus IgG isotype control-treated BRAF(V600E)-PTEN-/- melanomas. Representative IHC images and flow cytometry dot plots are provided. D. Serial tissue biopsy and qrt-PCR analysis of anti-PD-1 ab-treated versus IgG isotype control-treated BRAF(V600E)-PTEN-/- melanomas. All data is mean +/- SEM. *P<0.05

Back to article page